These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7999424)

  • 1. Timing of surgery influences survival in receptor-negative as well as receptor-positive breast cancer.
    Saad Z; Vincent M; Bramwell V; Stitt L; Duff J; Girotti M; Jory T; Heathcote G; Turnbull I; Garcia B
    Eur J Cancer; 1994; 30A(9):1348-52. PubMed ID: 7999424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor.
    Cooper LS; Gillett CE; Patel NK; Barnes DM; Fentiman IS
    Cancer; 1999 Nov; 86(10):2053-8. PubMed ID: 10570431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome.
    Mangia A; De Lena M; Barletta A; Marzullo F; Attolico M; Stea B; Petroni S; Labriola A; Cellamare G; Digiesi G; Altieri R; Schittulli F; Paradiso A
    J Exp Clin Cancer Res; 1998 Sep; 17(3):317-23. PubMed ID: 9894769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
    Goldhirsch A; Gelber RD; Castiglione M; O'Neill A; Thürlimann B; Rudenstam CM; Lindtner J; Collins J; Forbes J; Crivellari D; Coates A; Cavalli F; Simoncini E; Fey MF; Pagani O; Price K; Senn HJ
    Ann Oncol; 1997 Aug; 8(8):751-6. PubMed ID: 9332682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship of estrogen and progesterone receptors to the menstrual cycle and menopausal status at the time of breast surgery].
    Karbowski B; Jackisch C; Deppe B; Schneider HP
    Zentralbl Gynakol; 1999; 121(8):367-74. PubMed ID: 10486879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma.
    Pujol P; Daures JP; Brouillet JP; Chang S; Rouanet P; Bringer J; Grenier J; Maudelonde T
    Cancer; 2001 May; 91(10):1854-61. PubMed ID: 11346866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menstrual cycle and hormone receptor status in breast cancer patients.
    Atalay C; Kanliöz M; Altinok M
    Neoplasma; 2002; 49(4):278. PubMed ID: 12382029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
    Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
    Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
    Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
    Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
    Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
    J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.
    Grant CS; Ingle JN; Suman VJ; Dumesic DA; Wickerham DL; Gelber RD; Flynn PJ; Weir LM; Intra M; Jones WO; Perez EA; Hartmann LC
    J Clin Oncol; 2009 Aug; 27(22):3620-6. PubMed ID: 19487378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy.
    Holli K; Isola J; Hakama M
    Br J Cancer; 1995 Jan; 71(1):124-7. PubMed ID: 7819026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix.
    Konishi I; Fujii S; Nonogaki H; Nanbu Y; Iwai T; Mori T
    Cancer; 1991 Sep; 68(6):1340-50. PubMed ID: 1651807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the menstrual cycle on the concentrations of estrogen and progesterone receptors in primary breast cancer biopsies.
    Smyth CM; Benn DE; Reeve TS
    Breast Cancer Res Treat; 1988 Apr; 11(1):45-50. PubMed ID: 3382762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
    Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
    J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
    Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.